Active substance
Carbimazole
- SFDA 2
- NHS prices 4
- WHO EML 1
- Safety 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Carbimazole Macleods | 5 mg | Tablet · Oral use | 100 Blister | SAR 20.75 | Generic · Prescription | Macleods Pharmaceuticals Ltd. | Valid |
| NEO-MERCAZOLE 5MG TAB | 5 mg | Tablet · Oral use | 100 Bottle | SAR 21.85 | Generic · Prescription | AMDIPHARMA | Valid |
Indications — CHI Daman Drug Formulary
HYPERTHYROIDISM
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Carbimazole 10mg tablets | £87.45 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Carbimazole 15mg tablets | £312.19 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Carbimazole 20mg tablets | £2.06 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Carbimazole 5mg tablets | £1.32 | 100 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 18.7. Thyroid hormones and antithyroid medicines · core (EML); complementary (EMLc)
Therapeutic equivalent to methimazole for Thyrotoxicosis
Safety signals and safety-related labeling changes
- MHRA 20 Feb 2019 Carbimazole: increased risk of congenital malformations; strengthened advice on contraception
Carbimazole is associated with an increased risk of congenital malformations, especially when administered in the first trimester of pregnancy and at high doses. Women of childbearing potential should use effective contraception during treatment with carbimazole. - MHRA 20 Feb 2019 Carbimazole: risk of acute pancreatitis
If acute pancreatitis occurs during treatment with carbimazole, immediately and permanently stop treatment. Re-exposure to carbimazole may result in life-threatening acute pancreatitis with a decreased time to onset. - EMA PRAC 29 Nov 2018 PRAC signal: New information on the known risk of birth defects and neonatal disorders in case of exposure during pregnancy
Action for MAH: update of the product information: Yes - EMA PRAC 29 Nov 2018 PRAC signal: Pancreatitis
Action for MAH: update of the product information: Yes - EMA PRAC 12 Jul 2018 PRAC signal: Pancreatitis
Action for MAH: update of the product information: No - EMA PRAC 14 Jun 2018 PRAC signal: New information on the known risk of birth defects and neonatal disorders in case of exposure during pregnancy
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.